Business Description
CureVac NV
NAICS : 541714
ISIN : NL0015436031
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.69 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.18 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -1.91 | |||||
Beneish M-Score | -2.3 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.2 | |||||
3-Year EBITDA Growth Rate | -9 | |||||
3-Year EPS without NRI Growth Rate | -2.8 | |||||
3-Year Book Growth Rate | -19.3 | |||||
Future 3-5Y EPS without NRI Growth Rate | 45.9 | |||||
Future 3-5Y Total Revenue Growth Rate | 10.59 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 82.46 | |||||
9-Day RSI | 68.97 | |||||
14-Day RSI | 60.22 | |||||
6-1 Month Momentum % | -48.48 | |||||
12-1 Month Momentum % | -56.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.57 | |||||
Quick Ratio | 2.43 | |||||
Cash Ratio | 2.17 | |||||
Days Inventory | 69.38 | |||||
Days Sales Outstanding | 55.42 | |||||
Days Payable | 90.58 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.5 | |||||
Shareholder Yield % | -36.2 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -131.66 | |||||
Operating Margin % | -513.88 | |||||
Net Margin % | -484.05 | |||||
FCF Margin % | -601 | |||||
ROE % | -43.38 | |||||
ROA % | -29.97 | |||||
ROIC % | -67.59 | |||||
ROC (Joel Greenblatt) % | -99 | |||||
ROCE % | -35.74 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 11.95 | |||||
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.32 | |||||
EV-to-EBIT | -1.12 | |||||
EV-to-Forward-EBIT | -0.96 | |||||
EV-to-EBITDA | -1.23 | |||||
EV-to-Forward-EBITDA | -1.06 | |||||
EV-to-Revenue | 5.38 | |||||
EV-to-Forward-Revenue | 3.72 | |||||
EV-to-FCF | -0.9 | |||||
Price-to-Net-Current-Asset-Value | 3.1 | |||||
Price-to-Net-Cash | 4.82 | |||||
Earnings Yield (Greenblatt) % | -89.29 | |||||
FCF Yield % | -49.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
CureVac NV Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 53.758 | ||
EPS (TTM) (€) | -1.18 | ||
Beta | 0.91 | ||
Volatility % | 58.93 | ||
14-Day RSI | 60.22 | ||
14-Day ATR (€) | 0.10838 | ||
20-Day SMA (€) | 2.5048 | ||
12-1 Month Momentum % | -56.31 | ||
52-Week Range (€) | 2.096 - 10.96 | ||
Shares Outstanding (Mil) | 224.31 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CureVac NV Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CureVac NV Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
CureVac NV Frequently Asked Questions
What is CureVac NV(WBO:CVAC)'s stock price today?
When is next earnings date of CureVac NV(WBO:CVAC)?
Does CureVac NV(WBO:CVAC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |